Ophthotech definition

Ophthotech is sponsoring the Study (as that term is defined below) and has contracted with TFS (by separate Agreement) to coordinate, oversee and/or perform certain activities required for the conduct of the Study. len „zadávateľ“ alebo „Ophthotech“ je zadávateľom štúdie (ktorá je definovaná ďalej) a uzavrela zmluvu so spoločnosťou TFS (samostatnou zmluvou) o koordinácii, dohľade alebo vykonávaní určitých činností potrebných na vykonávanie štúdie. - The Institution and Investigator agree to - Inštitúcia a skúšajúci súhlasí s tým, že perform in Institution’s facilities located at Fakultná nemocnica Trenčín, Legionarska 28, 911 71 Trenčín the clinical study of Fovista™ (hereinafter, the “Study Drug”), entitled “A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FovistaTM (anti PDGF-B pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration”. - hereinafter the "Study", according to the protocol with number OPH1004, hereinafter the “Protocol”. vykoná v priestoroch inštitúcie nachádzajúcich sa na Fakultná nemocnica Trenčín, Legionarska 28, 911 71 Trenčín klinickú štúdiu lieku Fovista™ (ďalej len „skúšaný liek“) s názvom „Náhodné kontrolované skúšanie 3. fázy, s dvojitým zaslepením, za účelom stanovenia bezpečnosti a účinnosti intravitreálnej aplikácie lieku Fovista™ (Anti PDGF-B pegylovaný aptamér) v kombinácii s liekom Avastin®, alebo Eylea®, v porovnaní s monoterapiou liekom Avastin®, alebo Eylea®, pri liečbe pacientov so subfoveálnou neovaskulárnou (vlhkou) vekom podmienenou degeneráciou makuly “. ďalej len „štúdia“, podľa protokolu číslo OPH1004, ďalej len „protokol“. - The Institution ensures that the Principal - Inštitúcia zabezpečí, že Hlavný skúšajúci investigator (the “Investigator”) and study staff have ability to perform the Study and the site facilities are adequate to perform the Study.

Ophthotech or the “Company”). Subject to the terms of this Letter Agreement, your employment will end effective on the earliest of (i) Xxxxx 00, 0000, (xx) such date as may be mutually agreed between you and the Company, and (iii) such date as the Company terminates your employment for Cause, as that term is defined in the February 20, 2015 severance benefits agreement between you and the Company (the “Severance Agreement”) (as applicable, the “Separation Date”). By signing a copy of this Letter Agreement in the space provided below, you agree to the terms and conditions set forth herein.

Ophthotech or the “Company” means nominal defendant IVERIC bio, Inc. f/k/a/ Ophthotech Corporation, a Delaware corporation, and its affiliates, subsidiaries, predecessors, successors, and assigns.

Examples of Ophthotech in a sentence

• Excluded from the Class are: (i) Defendants; (ii) members of the immediate family of each Defendant; (iii) any Person who was an officer or director of Ophthotech during the Class Period; (iv) any entity in which any Defendant has or had a controlling interest; (v) any corporate parent and/or affiliate of Ophthotech; and (vi) the legal representatives, heirs, successors-in-interest, or assigns of any such excluded Person.

• Whereas the Phase 2b Trial had excluded patients with pure occult lesions, by requiring only the presence of SHRM for enrollment in the Phase 3 Trials, Ophthotech was permitting patients with pure occult lesions to be included in the Phase 3 Trials.

• In case of inclement weather, they need to listen to the local radio or television station for ―no school‖ announcements.

• Ophthotech anticipates that subsequent events and developments will cause its views to change.

• If one or more DLTs occur in the second set of 3 subjects, a discussion of safety data will be held among the Ophthotech medical team to review the observed toxicities and determine whether Cohort 1 may proceed.Once Cohort 1 has been fully enrolled, or if enrollment has been stopped due to one or more DLTs, then enrollment in the remaining 3 cohorts may commence.

• A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: www.ophthotech.com.

• Adequate drug accountability records include documentation of all trial drug supplies received, dispensed to trial subjects, and returned to Ophthotech Corp.At the end of the trial, all drug supplies and documentation will be reviewed and verified by the trial monitors.

• Conference Call/Web Cast Information Ophthotech will host a conference call/webcast to discuss the Company’s financial and operating results and provide a business update.

• David is also a Venture Partner at SV Health Investors and is Co-Founder and former CEO and Executive Chairman of IVERIC bio (formerly Ophthotech Corporation).

• The sites will be instructed to destroy unused trial drug supplies when the trial is completed, or the site may choose to return the drug to an Ophthotech Corp.

More Definitions of Ophthotech

Ophthotech or the “Company”) and the transition of your responsibilities as Executive Vice President, Chief Financial Officer & Business Officer and Treasurer (collectively, “CFO”). By the Company’s and your signing a copy of this Letter Agreement in the space provided below, the Company and you agree to the terms and conditions set forth herein.

Ophthotech or the “Company”). Subject to the terms of this Letter Agreement, your employment will end effective July 31, 2015 (the “Separation Date”). By signing a copy of this Letter Agreement in the space provided below, you agree to the terms and conditions set forth herein.